Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

Osteoporosis International

Volumn 11, Issue 4, 2000, Pages 331-337

  Eastell, Richard ^a,d   Devogelaer, J P ^b   Peel, N F A ^a   Chines, A A ^c   Bax, D E ^a   Sacco Gibson, N ^c   Nagant De Deuxchaisnes, C ^b   Russell, R G G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Glucocorticoid induced osteoporosis; Rheumatoid arthritis; Risedronate

Indexed keywords

GLUCOCORTICOID; PLACEBO; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH EROSION; STOMACH ULCER;

ADMINISTRATION, ORAL; AGED; ARTHRITIS, RHEUMATOID; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PREDNISOLONE;

EID: 0034124416     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980070122     Document Type: Article

References (27)

1. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39:179-801.
2. Luckert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern 1990;112:352-64.
3. Reid IR. Glucocorticoid osteoporosis: mechanisms and management. EurJ Endocrinol 1997;137:209-17.
4. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
5. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
6. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluations of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
7. Peel NFA, Moore DJ, Barrington NA, Bax DE, Eastell RA. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
8. Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981;52:111.
9. Verstraeten A, Dequeker J. Risk of vertebral fracture in women with rheumatoid arthritis. Ann Rheum Dis 1986;45:852-7.
10. Eastell R. Treatment of postmenopausal osteoporosis. N Eng J Med 1998;338:73-46.
11. Reid D, Cohen S, Pack S, Chines A, Ethgen E. Risedronate reduces the incidence of vertebral fractures in patients on chronic corticosteroid therapy. Arthritis Rheum 1998; 41(Suppl):S136.
12. Cohen S, Levy R, Keller M, Sewell KL, Boling E, Eusebio R, et al. Risedronate prevents corticosteroid-induced bone loss and decreases the risk of vertebral fractures. Arthritis Rheum 1998;41 (Suppl):S137.
13. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
14. Saag KG, Ernkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339:292-9.
15. Amin S, LaValley MP, Simms RW, Felson DT. A meta-analysis ranking efficacy of treatments for corticosteroid-induced osteoporosis (CSOP). Arthritis Rheum 1998;41(Suppl):S137.
16. McOsker J. Preclinical pharmacology of risedronate, a 3rd generation bisphosphonate [Abstract]. Fifth international symposium on bone, structure, function and disease. Sydney, Australia, April 23-25, 1990:47.
17. Roux C, Ravaud M, Cohen-Solal MC, DeVernejoul MC, Guillemant S, Cherruau S, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-9.
18. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy G. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067-71.
19. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998;22:51-5.
20. Siris ES, Chines AA, Altman RD, Brown J, Conrad C, Johnston JR, et al. Risedronate in the treatment of Paget's disease of bone: an open-label, multicenter study. J Bone Miner Res 1998;13:1032-8.
21. Melton LJ III, Lane AW, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-9.
22. Colwell A, Russell RGG, Eastell R. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993;23:341-9.
23. Adachi JD, Bensen WG, Anastassiades TP, Brown JP, Chines AA, Oiszynski WP. Etidronate in the prevention of corticosteroid-induced osteoporosis: one year follow-up on calcium only. Arthritis Rheum 1998;41(Suppl):S137.
24. Reid D, Devogelaer JP, Hughes R, Laan R, Adami S, Sacco-Gibson N, et al. Risedronate is effective and well tolerated in treating corticosteroid-induced osteoporosis. Arthritis Rheum 1998;41(Suppl):S303.
25. Young R, May H, Murphy S, Grey C, Compston JE. Rates of bone loss in peri- and postmenopausal women: a 4 year, prospective, population-based study. Clin Sci 1996; 91:307-12.
26. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
27. Dolan AL, Moniz C, Dasgupta B, Li F, Macintosh C, Todd P, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.